Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Keykhaei M, Sandhu AT, Hsue PY, Greene SJ, Ziaeian B, Kittleson M, Villarreal-Gonzalez M, Hallaj S, Ramsis M, Agarwal MA, Fonarow GC. National Impact of[...]

Mak S, Ghadimi S, Der-McLeod E, Naeem S, Moore V, Gil L, Chohan M, Zeidler M, Ash G, Fung C. Feasibility, acceptability, and usability of[...]

Bracken SJ, Weber JM, Neely ML, Swaminathan AC, Palmer SM, Wilfong EM, Chauffe AD, Volkmann ER. Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic[...]